Clinical Trial Update: A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ramucirumab plus best supportive care versus placebo plus best supportive care as second-line treatment for hepatocellular carcinoma af…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cyramza (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2015-03-26